Literature DB >> 11561604

Signaling pathways in pancreatic cancer.

S A Reddy1.   

Abstract

Pancreatic cancer is, indisputably, one of the most malignant gastrointestinal tumors. Although the etiology of this disease is unknown, it is clearly linked to alterations in the biologic activities of various signaling molecules. Aberrant signaling activities of growth factors and their receptors, transcription factors, and proteins that control the cell cycle have been increasingly implicated in the pathogenesis and dissemination of pancreatic tumors. It is indeed possible that several of these molecules are, in fact, part of a signaling network that has gone awry. This review summarizes some recent advances in an attempt to generate a working model for future investigations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561604

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  6 in total

1.  Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer.

Authors:  Jill P Smith; Sandra I Bingaman; David T Mauger; Harold H Harvey; Laurence M Demers; Ian S Zagon
Journal:  Open Access J Clin Trials       Date:  2010-03-01

2.  Data driven linear algebraic methods for analysis of molecular pathways: application to disease progression in shock/trauma.

Authors:  Mary F McGuire; M Sriram Iyengar; David W Mercer
Journal:  J Biomed Inform       Date:  2011-12-17       Impact factor: 6.317

3.  The molecular biology of pancreatic cancer.

Authors:  Michael A Abramson; Amarsanaa Jazag; Jill A van der Zee; Edward E Whang
Journal:  Gastrointest Cancer Res       Date:  2007

4.  A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.

Authors:  Ting Pan; Yiwen Zhang; Nan Zhou; Xin He; Cancan Chen; Liting Liang; Xiaobing Duan; Yingtong Lin; Kang Wu; Hui Zhang
Journal:  Oncotarget       Date:  2016-07-12

5.  Ubiquitin-independent, Proteasome-mediated targeted degradation of KRAS in pancreatic adenocarcinoma cells using an engineered ornithine decarboxylase/antizyme system.

Authors:  Yihui Ma; Jingjing Xu; Pei Huang; Xue Bai; Hanqing Gao
Journal:  IUBMB Life       Date:  2018-10-22       Impact factor: 3.885

6.  The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling.

Authors:  Duo Han; Shaihong Zhu; Xia Li; Zhiqiang Li; Hui Huang; Wenzhe Gao; Yunfei Liu; Hongwei Zhu; Xiao Yu
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.